Save
Share
Cite
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 85 • 2024 • Number 4
Read the Current Issue
Meta-Analysis
Changes in Cognition in Patients With Schizophrenia
Systematic Review
Diagnostic Assessment via Telehealth vs Face-to-Face
Original Research
Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans
Original Research
Bridge Symptoms Between Borderline Personality and PTSD
Original Research
Gepirone-ER and Sexual Function in Patients with MDD
Original Research
Medication Use and Lines of Treatment in Patients With Insomnia Disorder
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
